Search Results for: MTOR

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel PIK3CD phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta
  • PIP3 activates AKT signaling
  • Synthesis of PIPs at the plasma membrane
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • RET signaling
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Interleukin receptor SHC signaling
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Caffeine
  • XL765
  • TG100-115
  • 2-((9H-PURIN-6-YLTHIO)METHYL)-5-CHLORO-3-(2-METHOXYPHENYL)QUINAZOLIN-4(3H)-ONE
  • Idelalisib
  • Duvelisib
  • Fostamatinib
  • Copanlisib
Novel SLC2A5 solute carrier family 2 member 5
  • Neutrophil degranulation
  • Intestinal hexose absorption
Novel SLC9A1 solute carrier family 9 member A1
  • Hyaluronan uptake and degradation
  • Sodium/Proton exchangers
  • Amiloride
  • Homoserine Lactone
  • Cariporide
Novel CA6 carbonic anhydrase 6
  • Reversible hydration of carbon dioxide
  • Benzthiazide
  • Cyclothiazide
  • Zonisamide
  • Mafenide
  • Ellagic acid
Novel MECR mitochondrial trans-2-enoyl-CoA reductase
  • Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA
Novel NPPB natriuretic peptide B
  • Carvedilol
  • Oxymetholone
Novel SLC45A1 solute carrier family 45 member 1
HRAS HRas proto-oncogene, GTPase
  • SOS-mediated signalling
  • Activation of RAS in B cells
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB4 signaling
  • Signaling by SCF-KIT
  • Signalling to RAS
  • p38MAPK events
  • p38MAPK events
  • GRB2 events in EGFR signaling
  • SHC1 events in EGFR signaling
  • Downstream signal transduction
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • Tie2 Signaling
  • EGFR Transactivation by Gastrin
  • DAP12 signaling
  • SHC-related events triggered by IGF1R
  • FCERI mediated MAPK activation
  • NCAM signaling for neurite out-growth
  • EPHB-mediated forward signaling
  • Ras activation upon Ca2+ influx through NMDA receptor
  • VEGFR2 mediated cell proliferation
  • CD209 (DC-SIGN) signaling
  • Constitutive Signaling by EGFRvIII
  • SHC-mediated cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • Regulation of RAS by GAPs
  • RAF activation
  • RAF/MAP kinase cascade
  • MAP2K and MAPK activation
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • RAS signaling downstream of NF1 loss-of-function variants
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Insulin receptor signalling cascade
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • MET activates RAS signaling
  • Signaling by FGFR3 fusions in cancer
  • Signaling by FGFR3 point mutants in cancer
  • Activated NTRK2 signals through RAS
  • Erythropoietin activates RAS
  • Activated NTRK2 signals through FRS2 and FRS3
  • Activated NTRK3 signals through RAS
  • FLT3 Signaling
  • Constitutive Signaling by Overexpressed ERBB2
  • Estrogen-stimulated signaling through PRKCZ
  • RAS processing
  • RAS GTPase cycle mutants
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Hexane-1,6-Diol
  • Trifluoroethanol
  • Guanosine-5'-Triphosphate
  • Guanosine-5'-Diphosphate
  • N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE
  • Bladder cancer
  • Penile cancer
  • Squamous cell carcinoma
  • Thyroid cancer
  • Cervical cancer
  • Hepatocellular carcinoma
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
NRAS NRAS proto-oncogene, GTPase
  • SOS-mediated signalling
  • Activation of RAS in B cells
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB4 signaling
  • Signaling by SCF-KIT
  • Signalling to RAS
  • p38MAPK events
  • p38MAPK events
  • GRB2 events in EGFR signaling
  • SHC1 events in EGFR signaling
  • Downstream signal transduction
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • Tie2 Signaling
  • EGFR Transactivation by Gastrin
  • DAP12 signaling
  • SHC-related events triggered by IGF1R
  • FCERI mediated MAPK activation
  • NCAM signaling for neurite out-growth
  • Ras activation upon Ca2+ influx through NMDA receptor
  • VEGFR2 mediated cell proliferation
  • CD209 (DC-SIGN) signaling
  • Constitutive Signaling by EGFRvIII
  • SHC-mediated cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • Regulation of RAS by GAPs
  • RAF activation
  • RAF/MAP kinase cascade
  • MAP2K and MAPK activation
  • Negative regulation of MAPK pathway
  • Neutrophil degranulation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • RAS signaling downstream of NF1 loss-of-function variants
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Insulin receptor signalling cascade
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • MET activates RAS signaling
  • Signaling by FGFR3 fusions in cancer
  • Signaling by FGFR3 point mutants in cancer
  • Activated NTRK2 signals through RAS
  • Erythropoietin activates RAS
  • Activated NTRK2 signals through FRS2 and FRS3
  • Activated NTRK3 signals through RAS
  • FLT3 Signaling
  • Constitutive Signaling by Overexpressed ERBB2
  • Estrogen-stimulated signaling through PRKCZ
  • RAS processing
  • RAS GTPase cycle mutants
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
  • Oral cancer
  • Acute myeloid leukemia (AML)
  • Multiple myeloma
  • Adrenal carcinoma
  • Thyroid cancer
  • Hepatocellular carcinoma
  • Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
  • Malignant melanoma
EP300 E1A binding protein p300
  • Regulation of gene expression by Hypoxia-inducible Factor
  • RORA activates gene expression
  • Polo-like kinase mediated events
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Transcription and Translation
  • PPARA activates gene expression
  • PPARA activates gene expression
  • Formation of the beta-catenin:TCF transactivating complex
  • Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
  • NOTCH1 Intracellular Domain Regulates Transcription
  • NOTCH1 Intracellular Domain Regulates Transcription
  • NOTCH2 intracellular domain regulates transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • HATs acetylate histones
  • Attenuation phase
  • Transcriptional regulation of white adipocyte differentiation
  • Transcriptional regulation of white adipocyte differentiation
  • SUMOylation of transcription cofactors
  • Circadian Clock
  • B-WICH complex positively regulates rRNA expression
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
  • CD209 (DC-SIGN) signaling
  • Metalloprotease DUBs
  • Formation of TC-NER Pre-Incision Complex
  • Transcription-Coupled Nucleotide Excision Repair (TC-NER)
  • Dual incision in TC-NER
  • Gap-filling DNA repair synthesis and ligation in TC-NER
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • Regulation of TP53 Activity through Acetylation
  • Regulation of TP53 Activity through Methylation
  • PI5P Regulates TP53 Acetylation
  • Activation of the TFAP2 (AP-2) family of transcription factors
  • RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
  • RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
  • RUNX3 regulates NOTCH signaling
  • RUNX3 regulates NOTCH signaling
  • Regulation of RUNX3 expression and activity
  • RUNX3 regulates p14-ARF
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH4 Intracellular Domain Regulates Transcription
  • Estrogen-dependent gene expression
  • NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
  • NGF-stimulated transcription
  • NGF-stimulated transcription
  • TRAF3-dependent IRF activation pathway
  • TRAF6 mediated IRF7 activation
  • FOXO-mediated transcription of cell death genes
  • Transcriptional regulation of granulopoiesis
  • Transcriptional regulation of granulopoiesis
  • Regulation of FOXO transcriptional activity by acetylation
  • Regulation of FOXO transcriptional activity by acetylation
  • Rubinstein-Taybi syndrome
AKT1 AKT serine/threonine kinase 1
  • Activation of BAD and translocation to mitochondria
  • PIP3 activates AKT signaling
  • PIP3 activates AKT signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • MTOR signalling
  • AKT phosphorylates targets in the cytosol
  • AKT phosphorylates targets in the cytosol
  • AKT phosphorylates targets in the nucleus
  • Negative regulation of the PI3K/AKT network
  • eNOS activation
  • AKT-mediated inactivation of FOXO1A
  • Integrin signaling
  • Deactivation of the beta-catenin transactivating complex
  • CD28 dependent PI3K/Akt signaling
  • CTLA4 inhibitory signaling
  • G beta:gamma signalling through PI3Kgamma
  • Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA
  • KSRP (KHSRP) binds and destabilizes mRNA
  • VEGFR2 mediated vascular permeability
  • TP53 Regulates Metabolic Genes
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Interleukin-4 and Interleukin-13 signaling
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Acetylation
  • Regulation of TP53 Activity through Association with Co-factors
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Cyclin E associated events during G1/S transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
  • RAB GEFs exchange GTP for GDP on RABs
  • RUNX2 regulates genes involved in cell migration
  • Regulation of PTEN stability and activity
  • Extra-nuclear estrogen signaling
  • Negative regulation of NOTCH4 signaling
  • FLT3 Signaling
  • Regulation of localization of FOXO transcription factors
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • ATP
  • Arsenic trioxide
  • Genistein
  • Inositol 1,3,4,5-Tetrakisphosphate
  • Resveratrol
  • Archexin
  • Enzastaurin
  • Perifosine
  • N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  • 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
  • PTEN hamartoma tumor syndrome (PHTS), including: Cowden syndrome; Bannayan-Riley-Ruvalcaba syndrome; Proteus syndrome; Proteus-like syndrome
TRAF6 TNF receptor associated factor 6
  • PIP3 activates AKT signaling
  • MyD88:MAL(TIRAP) cascade initiated on plasma membrane
  • NOD1/2 Signaling Pathway
  • TICAM1, RIP1-mediated IKK complex recruitment
  • Regulated proteolysis of p75NTR
  • Downstream TCR signaling
  • NRIF signals cell death from the nucleus
  • NRIF signals cell death from the nucleus
  • p75NTR recruits signalling complexes
  • NF-kB is activated and signals survival
  • FCERI mediated NF-kB activation
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • activated TAK1 mediates p38 MAPK activation
  • JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
  • CLEC7A (Dectin-1) signaling
  • Ub-specific processing proteases
  • Ovarian tumor domain proteases
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • TICAM1,TRAF6-dependent induction of TAK1 complex
  • Interleukin-1 signaling
  • TRAF6 mediated IRF7 activation
  • TRAF6 mediated NF-kB activation
  • TRAF6 mediated NF-kB activation
  • IRAK1 recruits IKK complex
  • IKK complex recruitment mediated by RIP1
  • IRAK2 mediated activation of TAK1 complex
  • TRAF6-mediated induction of TAK1 complex within TLR4 complex
  • Alpha-protein kinase 1 signaling pathway
  • TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
  • MyD88 dependent cascade initiated on endosome
  • IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation
  • MyD88 cascade initiated on plasma membrane
STAT3 signal transducer and activator of transcription 3
  • Interleukin-6 signaling
  • BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Signaling by SCF-KIT
  • Signaling by cytosolic FGFR1 fusion mutants
  • Downstream signal transduction
  • Signalling to STAT3
  • Senescence-Associated Secretory Phenotype (SASP)
  • Signaling by Leptin
  • POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation
  • Association of TriC/CCT with target proteins during biosynthesis
  • Transcriptional regulation of pluripotent stem cells
  • Interleukin-10 signaling
  • Interleukin-4 and Interleukin-13 signaling
  • PTK6 Activates STAT3
  • PTK6 Activates STAT3
  • Interleukin-20 family signaling
  • MET activates STAT3
  • MET activates STAT3
  • Interleukin-15 signaling
  • Interleukin-35 Signalling
  • Interleukin-9 signaling
  • Interleukin-37 signaling
  • Interleukin-23 signaling
  • Interleukin-23 signaling
  • Interleukin-27 signaling
  • Interleukin-21 signaling
  • Transcriptional regulation of granulopoiesis
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Growth hormone receptor signaling
  • ENMD-1198
  • Other well-defined immunodeficiency syndromes, including the following seven diseases: Wiskott-Aldrich syndrome; DiGeorge syndrome; Hyper-IgE syndrome; X-linked lymphoproliferative syndrome; Immunodeficiency, Polyendocrinopathy, Enteropathy, X-linked Syndrome (IPEX); Cartilage-Hair Hypoplasia; Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)
  • Oral cancer
SUMO1 small ubiquitin like modifier 1
  • SUMO is conjugated to E1 (UBA2:SAE1)
  • SUMO is transferred from E1 to E2 (UBE2I, UBC9)
  • SUMO is proteolytically processed
  • SUMOylation of DNA damage response and repair proteins
  • SUMO E3 ligases SUMOylate target proteins
  • SUMOylation of transcription factors
  • SUMOylation of transcription factors
  • SUMOylation of ubiquitinylation proteins
  • SUMOylation of transcription cofactors
  • SUMOylation of transcription cofactors
  • SUMOylation of SUMOylation proteins
  • SUMOylation of intracellular receptors
  • SUMOylation of intracellular receptors
  • SUMOylation of chromatin organization proteins
  • SUMOylation of chromatin organization proteins
  • SUMOylation of RNA binding proteins
  • SUMOylation of DNA replication proteins
  • SUMOylation of DNA replication proteins
  • SUMOylation of DNA methylation proteins
  • SUMOylation of DNA methylation proteins
  • SUMOylation of immune response proteins
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Nonhomologous End-Joining (NHEJ)
  • Processing of DNA double-strand break ends
  • Formation of Incision Complex in GG-NER
  • G2/M DNA damage checkpoint
  • Regulation of IFNG signaling
  • Negative regulation of activity of TFAP2 (AP-2) family transcription factors
  • Negative regulation of activity of TFAP2 (AP-2) family transcription factors
  • Postmitotic nuclear pore complex (NPC) reformation
  • Maturation of nucleoprotein
  • Maturation of nucleoprotein
GSK3B glycogen synthase kinase 3 beta
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • AKT phosphorylates targets in the cytosol
  • Regulation of HSF1-mediated heat shock response
  • CRMPs in Sema3A signaling
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • B-WICH complex positively regulates rRNA expression
  • Signaling by GSK3beta mutants
  • S33 mutants of beta-catenin aren't phosphorylated
  • S37 mutants of beta-catenin aren't phosphorylated
  • S45 mutants of beta-catenin aren't phosphorylated
  • T41 mutants of beta-catenin aren't phosphorylated
  • APC truncation mutants have impaired AXIN binding
  • AXIN missense mutants destabilize the destruction complex
  • Truncations of AMER1 destabilize the destruction complex
  • Degradation of GLI2 by the proteasome
  • GLI3 is processed to GLI3R by the proteasome
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Ubiquitin-dependent degradation of Cyclin D
  • Regulation of RUNX2 expression and activity
  • Replication of the SARS-CoV-1 genome
  • Maturation of nucleoprotein
  • Maturation of nucleoprotein
  • Maturation of nucleoprotein
  • Replication of the SARS-CoV-2 genome
  • Lithium cation
  • 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione
  • SB-409513
  • AR-AO-14418
  • Staurosporine
  • Indirubin-3'-monoxime
  • 6-bromoindirubin-3'-oxime
  • Alsterpaullone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole
  • 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione
  • (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
  • N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  • 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
  • 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2'H-2,3'-biindol-2'-one
  • N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide
  • 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
  • ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
  • (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
  • Fostamatinib
  • Tideglusib
  • Lithium citrate
  • Lithium succinate
  • Lithium carbonate
PRKCA protein kinase C alpha
  • Calmodulin induced events
  • Disinhibition of SNARE formation
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • EGFR Transactivation by Gastrin
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Syndecan interactions
  • Acetylcholine regulates insulin secretion
  • Ca2+ pathway
  • Trafficking of GluR2-containing AMPA receptors
  • G alpha (z) signalling events
  • Depolymerisation of the Nuclear Lamina
  • HuR (ELAVL1) binds and stabilizes mRNA
  • WNT5A-dependent internalization of FZD4
  • VEGFR2 mediated cell proliferation
  • RHO GTPases Activate NADPH Oxidases
  • Response to elevated platelet cytosolic Ca2+
  • RET signaling
  • ROBO receptors bind AKAP5
  • ROBO receptors bind AKAP5
  • Phosphatidyl serine
  • Vitamin E
  • Tamoxifen
  • Ingenol mebutate
  • Aprinocarsen
  • Midostaurin
  • Perifosine
  • Ellagic acid
  • Bryostatin 1
  • alpha-Tocopherol succinate
  • D-alpha-Tocopherol acetate
CDC37 cell division cycle 37, HSP90 cochaperone
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Constitutive Signaling by EGFRvIII
  • Regulation of necroptotic cell death
  • Downregulation of ERBB2 signaling
  • RHOBTB2 GTPase cycle
  • Constitutive Signaling by Overexpressed ERBB2
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
PDPK1 3-phosphoinositide dependent protein kinase 1
  • GPVI-mediated activation cascade
  • GPVI-mediated activation cascade
  • PIP3 activates AKT signaling
  • Activation of AKT2
  • Downstream TCR signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • FCERI mediated NF-kB activation
  • Integrin signaling
  • CD28 dependent PI3K/Akt signaling
  • G beta:gamma signalling through PI3Kgamma
  • RSK activation
  • VEGFR2 mediated vascular permeability
  • VEGFR2 mediated cell proliferation
  • CLEC7A (Dectin-1) signaling
  • RHO GTPases activate PKNs
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Regulation of TP53 Degradation
  • Estrogen-stimulated signaling through PRKCZ
  • Estrogen-stimulated signaling through PRKCZ
  • Celecoxib
  • Inositol 1,3,4,5-Tetrakisphosphate
  • 7-Hydroxystaurosporine
  • Bisindolylmaleimide VIII
  • Staurosporine
  • Bisindolylmaleimide I
  • Dexfosfoserine
  • 10,11-dimethoxy-4-methyldibenzo[c,f]-2,7-naphthyridine-3,6-diamine
  • 5-HYDROXY-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-2-ONE
  • 1-{2-OXO-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-5-YL}UREA
  • 2-(1H-imidazol-1-yl)-9-methoxy-8-(2-methoxyethoxy)benzo[c][2,7]naphthyridin-4-amine
  • 3-(1H-indol-3-yl)-4-(1-{2-[(2S)-1-methylpyrrolidinyl]ethyl}-1H-indol-3-yl)-1H-pyrrole-2,5-dione
  • 3-[1-(3-AMINOPROPYL)-1H-INDOL-3-YL]-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE
  • Fostamatinib
IRS1 insulin receptor substrate 1
  • PI3K Cascade
  • IRS-mediated signalling
  • SOS-mediated signalling
  • SOS-mediated signalling
  • PIP3 activates AKT signaling
  • Interleukin-7 signaling
  • PI3K/AKT activation
  • PI3K/AKT activation
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • IRS-related events triggered by IGF1R
  • Signaling by Leptin
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • IRS activation
  • Signal attenuation
  • Activated NTRK3 signals through PI3K
  • Growth hormone receptor signaling
  • [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
ESR1 estrogen receptor 1
  • Nuclear signaling by ERBB4
  • PIP3 activates AKT signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Nuclear Receptor transcription pathway
  • SUMOylation of intracellular receptors
  • Ovarian tumor domain proteases
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • RUNX1 regulates estrogen receptor mediated transcription
  • ESR-mediated signaling
  • RUNX1 regulates transcription of genes involved in WNT signaling
  • Regulation of RUNX2 expression and activity
  • Regulation of RUNX2 expression and activity
  • Extra-nuclear estrogen signaling
  • Estrogen-dependent gene expression
  • Diethylstilbestrol
  • Chlorotrianisene
  • Conjugated estrogens
  • Desogestrel
  • Levonorgestrel
  • Progesterone
  • Lindane
  • Raloxifene
  • Toremifene
  • Medroxyprogesterone acetate
  • Testosterone
  • Mitotane
  • Estrone
  • Tamoxifen
  • Hexachlorophene
  • Estradiol
  • Ethynodiol diacetate
  • Dobutamine
  • Clomifene
  • Dienestrol
  • Fulvestrant
  • Norgestimate
  • Ethinylestradiol
  • Melatonin
  • Trilostane
  • Naloxone
  • Fluoxymesterone
  • Estramustine
  • Mestranol
  • Danazol
  • Oxybenzone
  • Allylestrenol
  • Zinc
  • Genistein
  • Prasterone
  • Benzophenone
  • Equilin
  • Compound 19
  • Resveratrol
  • Compound 18
  • Phthalic Acid
  • Pyrazole
  • Stanolone
  • Naringenin
  • Compound 4-D
  • 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
  • Quercetin
  • Afimoxifene
  • 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
  • Estriol
  • Estrone sulfate
  • Quinestrol
  • Phenolphthalein
  • Permethrin
  • Ospemifene
  • AP1081
  • Custirsen
  • NP-50301
  • CHF 4227
  • TAS-108
  • Lasofoxifene
  • Arzoxifene
  • Elacestrant
  • Bazedoxifene
  • Methyltestosterone
  • beta-Naphthoflavone
  • 17-METHYL-17-ALPHA-DIHYDROEQUILENIN
  • 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol
  • [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE
  • 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL
  • (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
  • (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL
  • 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
  • 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
  • Hexestrol
  • dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate
  • Erteberel
  • N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol
  • 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL
  • DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE
  • 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
  • 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL
  • 2-(4-hydroxyphenyl)benzo[b]thiophen-6-ol
  • Tibolone
  • Eugenol
  • Synthetic Conjugated Estrogens, A
  • Synthetic Conjugated Estrogens, B
  • Polyestradiol phosphate
  • Norethynodrel
  • Octocrylene
  • Homosalate
  • Enzacamene
  • Zeranol
  • Ractopamine
  • Gestrinone
  • Propyl Gallate
  • 2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol
  • Testosterone cypionate
  • Testosterone enanthate
  • Testosterone undecanoate
  • Stanolone acetate
  • Estradiol acetate
  • Estradiol benzoate
  • Estradiol cypionate
  • Estradiol dienanthate
  • Estradiol valerate
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Estriol tripropionate
  • Fluoroestradiol F-18

Page 1 out of 3 pages